News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
285,194 Results
Type
Article (15024)
Company Profile (299)
Press Release (269865)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (80386)
Career Advice (168)
Deals (13603)
Drug Delivery (41)
Drug Development (50932)
Employer Resources (32)
FDA (5916)
Job Trends (5375)
News (146460)
Policy (10404)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (923)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21876)
ALS (124)
Alzheimer's disease (1033)
Antibody-drug conjugate (ADC) (241)
Approvals (6110)
Artificial intelligence (258)
Autoimmune disease (111)
Automation (9)
Bankruptcy (109)
Best Places to Work (4767)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3142)
Cardiovascular disease (239)
Career advice (153)
Career pathing (7)
CAR-T (221)
CDC (5)
Cell therapy (569)
Cervical cancer (14)
Clinical research (43858)
Collaboration (1155)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1139)
CRISPR (86)
C-suite (553)
Cystic fibrosis (112)
Data (4329)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1393)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (50)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (32021)
Editorial (25)
Employer branding (4)
Employer resources (30)
Events (51923)
Executive appointments (626)
FDA (7675)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (982)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (505)
Government (1160)
Grass and pollen (3)
Guidances (172)
Healthcare (6699)
HIV (18)
Huntington's disease (43)
IgA nephropathy (76)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (68)
Infectious disease (1245)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7503)
IRA (13)
Job creations (876)
Job search strategy (135)
JPM (41)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1630)
Liver cancer (42)
Longevity (11)
Lung cancer (422)
Lymphoma (252)
Machine learning (24)
Management (7)
Manufacturing (378)
MASH (133)
Medical device (2734)
Medtech (2743)
Mergers & acquisitions (6730)
Metabolic disorders (729)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (230)
Neuropsychiatric disorders (70)
Neuroscience (1953)
Neurotech (1)
NextGen: Class of 2026 (2051)
Non-profit (872)
Now hiring (30)
Obesity (331)
Opinion (129)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (302)
Patient recruitment (330)
Peanut (43)
People (26742)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15501)
Phase 2 (20332)
Phase 3 (12932)
Pipeline (3267)
Policy (94)
Postmarket research (870)
Preclinical (6538)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (240)
Rare diseases (648)
Real estate (1457)
Recruiting (13)
Regulatory (9996)
Reports (19)
Research institute (975)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (124)
Series A (182)
Series B (136)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (34)
Tariffs (18)
The Weekly (62)
Vaccines (334)
Venture capital (69)
Weight loss (175)
Women's health (25)
Worklife (2)
Date
Last 7 days (348)
Last 30 days (1233)
Last 365 days (17968)
2026 (1663)
2025 (18239)
2024 (20687)
2023 (22667)
2022 (27278)
2021 (28402)
2020 (23830)
2019 (16442)
2018 (11892)
2017 (13896)
2016 (11957)
2015 (14478)
2014 (10507)
2013 (7569)
2012 (7610)
2011 (7715)
2010 (7504)
Location
Africa (162)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18400)
Australia (3140)
California (7084)
Canada (1850)
China (777)
Colorado (246)
Connecticut (252)
Delaware (236)
Europe (39593)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (397)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (747)
Massachusetts (5589)
Michigan (110)
Minnesota (248)
Mississippi (3)
Missouri (33)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1707)
New Mexico (13)
New York (1768)
North Carolina (825)
North Dakota (6)
Northern California (3482)
Ohio (178)
Oklahoma (11)
Oregon (24)
Pennsylvania (1282)
Puerto Rico (9)
Rhode Island (25)
South America (225)
South Carolina (9)
Southern California (2806)
Tennessee (41)
Texas (905)
United States (23446)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (602)
West Virginia (1)
Wisconsin (45)
285,194 Results for "prevail therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
pipeline
Lilly Axes 3 Therapies Amid Pipeline-in-a-Product Push for GLP-1
One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.
February 5, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Prilenia and Ferrer Announce FDA Clearance to Start the “PREVAiLS” Pivotal Phase 3 Study with Pridopidine in ALS
December 12, 2025
·
9 min read
Press Releases
Synthego Prevails In Patent Appeal Confirming Agilent CRISPR Patents Are Invalid
June 12, 2025
·
1 min read
Bio NC
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
April 16, 2024
·
11 min read
Press Releases
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy Division
May 5, 2025
·
3 min read
Press Releases
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
April 29, 2025
·
3 min read
Press Releases
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
May 15, 2025
·
12 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Business
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Sangamo Therapeutics, Inc. today announced it has signed an evaluation and option agreement with Prevail Therapeutics through which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.
July 17, 2023
·
4 min read
Press Releases
CorMedix Therapeutics Announces Share Repurchase Program
February 2, 2026
·
4 min read
1 of 28,520
Next
